Novel SARS-COV-2/COVID-19: an update of prevalence, modes of transmission, clinical manifestations, prevention and management
Abstract
A new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) associated with human to human transmission and extreme human sickness has been as of late announced from the city of Wuhan in China. This epidemic had spread to 210 countries and territories around the world with 6,049,380 confirmed cases, including 367,230 deaths, as of May 30, 2020, so the World Health Organization declared it as a Public Health Emergency of worldwide. It can cause serious respiratory diseases along with enteric, heart and neurological diseases, especially in immunocompromised patients. The reported symptoms include fever, coughing, sore throat, fatigue, headache, diarrhea, hemoptysis. trouble breathing, blue lips or face, persistent pain or pressure in the chest, confusion and excessive drowsiness. Preventive measures such as masks, frequent hand washing, staying home when sick, avoid public contact, and quarantines are being recommended for reducing the transmission. To date, no specific antiviral treatment is proven yet. There is a need to increase the knowledge of health care professionals regarding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, control, and management. For this, they must know about the prevalence, clinical manifestation, modes of transfer, control measures and management, etc. There must be a special task force that considers raising public awareness in the regions where the virus attacks. They must guide the people with the signs and symptoms of the disease.
Keywords
References
- 1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2001316.
- 2. Wang C, Wang X. Prevalence, nosocomial infection and psychological prevention of novel coronavirus infection. Chin General Pract Nurs. 2020;18:2–3.
- 3. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD: Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls Publishing, Treasure Island, FL; 2020.
- 4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.
- 5. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China—key questions for impact assessment. N Engl J Med. 2020; 382: 692-694.
- 6. van Doremalen N, Morris D, Bushmaker T et al. Aerosol and Surface Stability of SARS-CoV-2 as compared with SARSCoV-1. New Engl J Med 2020 doi: 10.1056/NEJMc2004973.
- 7. Mehmet Ozaslan, Muhamad Safdar, I. Halil Kilic and Rozhgar A. Khailany, 2020. Practical Measures to Prevent COVID-19: A Mini-Review. Journal of Biological Sciences, 20: 100-102.
- 8. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14: 523-534.
- 9. Liu J, Liao X, Qian S et al. Community transmission of severe acute respiratory syndrome coronavirus 2, Shenzhen, China, 2020. Emerg Infect Dis 2020 doi.org/10.3201/eid2606.200239
- 10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.